Chronic myeloid leukaemia therapy Scemblix receives NICE final draft recommendation in Britain
from PharmaTimes: News RSS https://ift.tt/GhyY0n2
Post Top Ad
Friday, 1 July 2022
Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment